Blood: the Fountain of Youth?
On CBS News, Dr. Aubrey de Grey discusses recent SRF-supported discoveries on the role of blood-borne factors in aging - research which may provide new therapies for neurodegenerative diseases like Alzheimer's, as well as other age-related conditions.
2018 Summer Scholars Program
Information about the 2018 SRF Summer Scholars Program is now available. Check back on December 1 for the complete list of research project options and the online application.
Check out all the latest news from SENS Research Foundation in our November newsletter. You might also like to check out the archive of past messages, or subscribe to our mailing list to make sure you don't miss out on future updates!
Dr. Kirkland at Undoing Aging 2018
SRF is delighted to announce a new project in the lab of Prof. David Spiegel at Yale. Building on our successful project to synthesise the crosslink glucosepane, Prof. Spiegel will now develop antibodies to quantify its accumulation in the aging body.
2018 Undoing Aging Conference
Antoxerene raises $1.5M
Live Long and Prosper
In a new interview for Billionaire.com, Tara Wilkinson asks SRF Chief Science Officer Dr. Aubrey de Grey about the progress made in rejuvenation medicine since SENS was first conceived - as well as the longer-term outlook for healthy life extension.
Annual Report Released
Our new Annual Report has been released! It's packed with info on our research projects, education programs, and outreach activities - and on Project|21, designed to move rejuvenation biotechnology into human clinical trials by 2021.
Zoomer Radio Interview
Maximally Modifiable Mice
SRF's third new collaboration with the Buck Institute for Research on Aging is focused on developing a major improvement in gene therapy techniques. Hosted in Dr. Brian Kennedy's laboratory, the project will enable safer gene editing for future clinical work.
We're delighted to announce another new collaboration with the Buck Institute for Research on Aging: Dr. Judith Campisi will host a project seeking ways to eliminate senescent immune cells, which contribute to a vicious cycle of age-related decline in immune function.
Silicon Valley vs. Death
Tad Friend of The New Yorker presents a wide-ranging review of the various initiatives currently under way to extend healthy human lifespans - discussing the work of SENS Research Foundation, Google's Calico, Unity Biotechnology, and many others.
Rejuvenating the Mitochondria
As part of Google's Giving Week, MitoSENS project leader Dr. Matthew O'Connor gave a Tech Talk on December 9th introducing SRF and our "damage repair" approach to fighting aging - followed by an update on our progress in repairing defective mitochondria.
Aging Runs In The Blood
Surgically connecting young and old mice reverses some aspects of aging, but isn't practical for humans! Fortunately for us, new SRF-funded work shows that transfusions of young blood produce many of the same benefits - paving the way towards human trials.
More Progress in Senolytics
Deleting senescent cells from mice delays many age-related diseases. A recent paper from the Unity Biotechnology team, who aim to start human trials in 12-18 months, now identifies atherosclerosis as another deadly condition which may be prevented by senolytic drugs.
Our 115-Year Shelf Life?
A recent demographic analysis in Nature by Vijg et al. has attracted global attention after concluding that there is a "natural limit" of around 115 years to human lifespans - but has also been criticised for undue pessimism regarding future medical advances.
Funding a Cure for Aging
Project|21's first patron, German internet entrepeneur Michael Greve, has formally announced a list of the research efforts that will be supported over the next year by the initial $1m tranche of his donation - as well as the startup companies receiving seed funds.
SENS Research Foundation has commissioned a series of 8 animations, narrated by actor Edward James Olmos, to explain the concept of SENS and some of the therapies that we're developing to end age-related disease for good.